Progen Industries Ltd (PGLAF) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Progen Industries Ltd (PGLAF)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Henrik	10/4/2006 1:26:30 AM
	of 349

Progen changes its NASDAQ ticker symbol to PGLA Brisbane, Australia. 4 October 2006. Progen Industries (ASX: PGL, NASDAQ: PGLAF), a global developer of anti-cancer drugs, today announced a change in its NASDAQ Capital Market ticker symbol from PGLAF to PGLA. The change is effective from 9 October 2006. About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases. Progen’s three key areas of focus are: • Clinical Development - via a focused clinical trial program involving its two compounds PI-88 and PI-166. • Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes. • Manufacturing Services – PI-88 manufacturing and supply for the clinical program and contract biological process development, manufacture and quality assurance services. Keywords - Progen, cancer, NASDAQ Web links to selected recent news and other information about Progen: Progen’s Financial Year ends with a positive outlook for 2007 www.progen.com.au/?page=nepress2006.html Progen prepares for accelerated clinical development www.progen.com.au/?page=nepress2006.html Progen meets with FDA www.progen.com.au/?page=nepress2006.html New CEO www.progen.com.au/?page=nepress2006.html Open Briefing: New Trial & Update www.progen.com.au/?page=nepress2005.html AUSIndustry Grant Offered ($3.4M) www.progen.com.au/?page=nepress2005.html PI-88 mode of action www.progen.com.au/?page=repi-88.html Progen’s drug development pipeline www.progen.com.au/?page=pihome.html Progen Industries Ltd www.progen.com.au Media and Investor Relations: Rebecca Wilson Buchan Consulting rwilson@bcg.com.au Ph: (02) 9237 2800 / 0417 382 391 Progen Information: Sarah Meibusch Director, Business Development Progen Industries Limited Sarah.Meibusch@progen.com.au Ph: +61 7 3842 3333 Linton Burns CFO Progen Industries Limited linton.burns@progen.com.au Ph: : +61 7 3842 3333

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next